TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Structural brain imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time-weighted average MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30 day survival after hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Readmission after hospital discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Angiographic in-stent % diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antimicrobial log10 Reductions From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Responder Rate at 6 Hours Post-Product Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occurrence of solicited injection site or systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of unsolicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Transcutaneous O2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of circulating endothelial progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the ankle joint space width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reproducibility of IHC4 score testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Arisen of an infectious complication
Endpoint domain: Adverse events/effects
Primary endpoint: Arisen of non infectious complication
Endpoint domain: Adverse events/effects
Primary endpoint: hematologic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Doppler measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative Delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Change in scores on the Brief Symptom Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of intrahepatic fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting CTTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post Traumatic Stress Disorder Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DMO distal femur at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: Medication administration errors rate
Endpoint domain: Adverse events/effects
Primary endpoint: Median Time to Achieve Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anxiety and Depression Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ovarian reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perinatal morti-morbidity
Endpoint domain: Mortality/survival
Primary endpoint: successful sedation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perceived health status
Endpoint domain: Life impact
Primary endpoint: Mean change in HIV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra-ocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: objective refraction after fog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: failure to insert line
Endpoint domain: Adverse events/effects
Primary endpoint: mechanical complications of intravenous line insertion
Endpoint domain: Adverse events/effects
Primary endpoint: infectious complications of intravenous lines
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Oxygen Uptake Kinetics (VO2 Kinetics)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eyes Achieving Monocular Photopic DCIVA 0.20 logMAR or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Gross Motor Function Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to amiodarone use
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events related to atrial fibrillation
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events related to underlying heart disease
Endpoint domain: Adverse events/effects
Primary endpoint: T1 measurement (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Net Adverse Clinical Events (NACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in sensory nerve conduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in oxyneurogram index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: User's ability to obtain the enhanced meter feature
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical success defined by the need for no additional antibiotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute incidence of erectile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aberrant Behavior Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Atopic sensitisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean number of cumulative combined unique active lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (AUC and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugyl Myer assessment tool for upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG power in alpha, delta, gamma, and theta waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lag Time (Tlag) of Ridaforolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From 0 to Infinity (AUC0-∞) of Ridaforolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Ridaforolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pocket formation
Endpoint domain: Adverse events/effects
Primary endpoint: Threshold hearing levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medial compartment knee cartilage thickness and volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Level of serum tenascin-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of left and right ventricular early diastolic tissue velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Who Completed Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Discrimination between consciousness and unconsciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Ventricular Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gait pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression-free Survival at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Adverse Effects (Grade 3 or Higher)
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and Severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total score of the SNAP-V questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of serious adverse drug reactions (SADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Pathological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Local and systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term antidepressant efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Flow Mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wake Time After Sleep Onset (PSG WASO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Airway Leak Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient Rating of Shared Decision Making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Doctor Facilitation Subscale of the Perceived Involvement in Care Scale
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patients' Feeling of Respect by Their Doctor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean infusion rate of intraoperative remifentanil and propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU-AW development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anthropometric measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasonographic measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D Head deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Procedure Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with CMV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brief Symptom Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postsurgical catheter-related bladder discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage Change From Baseline in 10m Sprint Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Agility T-Test Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Squat Jump Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear or Almost Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=75 Percent Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance of stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal walking pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface EMG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) Per RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With a Partial Response, Progressive Disease, or Stable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in Conners 3 Global Index - Parent
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Body Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ADLER Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Pre-intervention on the Virtual Reality Perspective Taking Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Pre-intervention on the Acknowledgement of Other Perspective Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Pre-intervention in Brain Activity in Response to Self Pain vs. Other Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Distance Control at 12-Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Distance Control at 18-Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Visual Reception Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Fine Motor Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Receptive Language Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Expressive Language Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor and Language Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HbSS and HbA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sulcular bleeding index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Pulmonary Embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in point prevalence of genotype-specific HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Difference in point prevalence of chlamydia trachomatis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fusion Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient/provider satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in VLDL TG palmitate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Motor Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under ROC curve based on subjects' maximum POM scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity based on subjects' maximum BI-RADS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity based on subjects' maximum BI-RADS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Pure Red Cell Aplasia (PRCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Positive Serum Erythropoietin (EPO) Antibodies Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptability of FruitiVits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood health parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood ketone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiovascular
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet aggregability (AUC for ADP-induced aggregation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HBV-DNA <400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HBsAg quantitative loss and anti-HBs seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients alive and without progression
Endpoint domain: Mortality/survival
Primary endpoint: biochemical indicators of bone formation and bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Manchester-Oxford Foot Questionnaire (MOXFQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent change in Low-density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to lost to follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mini International Neuropsychiatric Interview (M.I.N.I.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: State - Trait Anxiety Inventory Form Y
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients undergoing adverse events (AEs) or serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in global left ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neuroinflammation assessed by PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain function assessed by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 5-yr invasive disease-free survival (IDFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in Fear of Flying Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence and Severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Safety Profile
Endpoint domain: Adverse events/effects
Primary endpoint: glycemic remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VEGFR-2 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PD-L1 gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival in the ICU
Endpoint domain: Mortality/survival
Primary endpoint: Phrenic Nerve Complication Free Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Eccentric hip adductor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient rated pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Soluble Vascular Cell Adhesion Molecule-1 (sVCAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peak Epinephrine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum tolerated dose (MTD) for selected regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fistula Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of surface molecules on eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes